Evidence map›Paper›PMID 32611400›Full record

ArticleBMC infectious diseases2020

A retrospective cohort investigation of seroprevalence of Marburg virus and ebolaviruses in two different ecological zones in Uganda.

Luke Nyakarahuka, Ilana J Schafer, Stephen Balinandi, Sophia Mulei, Alex Tumusiime, Jackson Kyondo, Barbara Knust, Julius Lutwama, Pierre Rollin, Stuart Nichol and 1 more

Open access · goldAbstract read
In one paragraph

Article in BMC infectious diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.3field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Luke NyakarahukaArbovirology, Emerging and Re-emerging Diseases, Uganda Virus Research Institute , Entebbe, Uganda. nyakarahuka@gmail.com.ORCID http://orcid.org/0000-0002-2944-9157
Ilana J SchaferCentres for Disease Control and Prevention, Atlanta, USA.
Stephen BalinandiArbovirology, Emerging and Re-emerging Diseases, Uganda Virus Research Institute , Entebbe, Uganda.
Sophia MuleiArbovirology, Emerging and Re-emerging Diseases, Uganda Virus Research Institute , Entebbe, Uganda.
Alex TumusiimeArbovirology, Emerging and Re-emerging Diseases, Uganda Virus Research Institute , Entebbe, Uganda.
Jackson KyondoArbovirology, Emerging and Re-emerging Diseases, Uganda Virus Research Institute , Entebbe, Uganda.
Barbara KnustCentres for Disease Control and Prevention, Atlanta, USA.
Julius LutwamaArbovirology, Emerging and Re-emerging Diseases, Uganda Virus Research Institute , Entebbe, Uganda.
Pierre RollinCentres for Disease Control and Prevention, Atlanta, USA.
Stuart NicholCentres for Disease Control and Prevention, Atlanta, USA.
Trevor ShoemakerCentres for Disease Control and Prevention, Atlanta, USA.
Uganda Virus Research Institute · UGMakerere University · UG

Funding

HSRD VA PEC 13-001NCEZID CDC HHS RFA-CK-13-001
6 · The paper itself

Abstract

backgroundUganda has experienced seven Ebola Virus Disease (EVD) outbreaks and four Marburg Virus Disease (MVD) outbreaks between 2000 and 2019. We investigated the seroprevalence and risk factors for Marburg virus and ebolaviruses in gold mining communities around Kitaka gold mine in Western Uganda and compared them to non-mining communities in Central Uganda.

methodsA questionnaire was administered and human blood samples were collected from three exposure groups in Western Uganda (gold miners, household members of miners, non-miners living within 50 km of Kitaka mine). The unexposed controls group sampled was community members in Central Uganda far away from any gold mining activity which we considered as low-risk for filovirus infection. ELISA serology was used to analyse samples, detecting IgG antibodies against Marburg virus and ebolaviruses (filoviruses). Data were analysed in STATA software using risk ratios and odds ratios.

resultsMiners in western Uganda were 5.4 times more likely to be filovirus seropositive compared to the control group in central Uganda (RR = 5.4; 95% CI 1.5-19.7) whereas people living in high-risk areas in Ibanda and Kamwenge districts were 3.6 more likely to be seropositive compared to control group in Luweeero district (RR = 3.6; 95% CI 1.1-12.2). Among all participants, filovirus seropositivity was 2.6% (19/724) of which 2.3% (17/724) were reactive to Sudan virus only and 0.1% (1/724) to Marburg virus. One individual seropositive for Sudan virus also had IgG antibodies reactive to Bundibugyo virus. The risk factors for filovirus seropositivity identified included mining (AOR = 3.4; 95% CI 1.3-8.5), male sex (AOR = 3.1; 95% CI 1.01-9.5), going inside mines (AOR = 3.1; 95% CI 1.2-8.2), cleaning corpses (AOR = 3.1; 95% CI 1.04-9.1) and contact with suspect filovirus cases (AOR = 3.9, 95% CI 1.04-14.5).

conclusionsThese findings indicate that filovirus outbreaks may go undetected in Uganda and people involved in artisan gold mining are more likely to be exposed to infection with either Marburg virus or ebolaviruses, likely due to increased risk of exposure to bats. This calls for active surveillance in known high-risk areas for early detection and response to prevent filovirus epidemics.

Indexed as

Disease OutbreaksAdolescentAdultAgedAged, 80 and overAnimalsChildChild, PreschoolChiropteraEbolavirusEnzyme-Linked Immunosorbent AssayFemaleHemorrhagic Fever, EbolaHumansMaleMarburgvirusEbola virus diseaseEbolavirusesELISAEpidemiologyFilovirusMarburg virus diseaseSeroprevalenceUganda

Identifiers

PMID32611400
PMCPMC7329513
OpenAlexW3040304153

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.